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ABSTRACT 1 
Background 2 
While exercise testing is increasingly used as a prognostic indicator in Cystic Fibrosis 3 
(CF), it is reported to be underused in UK CF centres, particularly in children. Here, 4 
we evaluated the cardiopulmonary exercise testing (CPET) results in children and 5 
young people with CF at CF annual review and its possible clinical value.  6 
 7 
Method 8 
An observational study comparing CPET results using a cycle ergometer ramp test 9 
(peak oxygen uptake (VO2peak)) and pulmonary function (forced expiratory volume in 10 
1 second (FEV1)) was performed with body mass index (BMI) used as a disease 11 
severity marker. Data were identified from clinical case notes and our CF database. 12 
 13 
Results  14 
Thirty-eight children and young people (mean age 11±2.4; range 7-14 years; 17 15 
males and 21 females) completed at least one CPET with 95 % achieving technically 16 
satisfactory tests allowing measurement of VO2peak. Mean VO2peak was 107±17.6% 17 
predicted, range 74 - 150% predicted, with 8% having a reduced VO2peak of <85% of 18 
predicted. Mean FEV1 z-score was -0.77±1.24, range -4.42 to 2.24. We did not 19 
demonstrate a significant correlation between VO2peak % predicted and FEV1 z-score 20 
(r=0.25, p=0.13), or between VO2peak % predicted and BMI z-score (r=-0.05, p=0.77). 21 
Twenty-eight of 38 completed a second CPET the following year with 71% showing a 22 
decline in VO2peak, (mean decline of 8% of predicted value, equivalent to 3.8 23 
mL/kg/min). 24 
Conclusion 1 
CPET is feasible with 95 % of children and young people achieving technically 2 
satisfactory assessments starting from age 7. In this group with relatively mild CF, 3 
mean VO2peak was normal with no significant correlation between VO2peak and FEV1 or 4 
BMI, as markers of disease severity. The majority demonstrated a normal VO2peak. 5 
However, 71% showed a downward trend on repeat testing 12-18 months later. 6 
 7 
What is already known on this topic 8 
 Exercise testing is not widely used in cystic fibrosis (CF) centres in the UK. 9 
 Peak oxygen uptake (VO2peak)and forced expiratory volume in 1 s (FEV1) are 10 
independent predictors of mortality in CF. 11 
 12 
What this study adds 13 
 We demonstrate that it is feasible to include a cardiopulmonary exercise test 14 
(CPET) as part of annual review in children and young people aged 7 years 15 
and above. 16 
 In mild disease, there is no significant correlation between VO2peak and FEV1 17 
or body mass index. 18 
 A decline in fitness can be used as a trigger for more intensive physiotherapy 19 
intervention. 20 
 21 
 22 
 23 
24 
INTRODUCTION 1 
 2 
Aerobic fitness has been found to be an independent predictor of mortality and 3 
morbidity in patients with cystic fibrosis (CF) [1,2,3]. At present, the UK CF trust 4 
guidelines recommend exercise testing at CF annual review when clinically indicated 5 
[4]. The European Cystic Fibrosis Exercise Working Group recommend that full 6 
cardiopulmonary exercise testing (CPET) should be performed routinely in children 7 
aged ≥10 years [5]. Exercise testing is reported to be underused in UK CF centres 8 
with field-based walking tests used most commonly [6]. To our knowledge, there are 9 
no studies assessing the prognostic value of the 6 min walk test (6MWT) in children 10 
with CF, and only limited reports in adults [7]. The prognostic value of an incremental 11 
shuttle test [8] in children with CF is also unknown. In contrast, peak oxygen uptake  12 
(VO2peak) has been shown to predict mortality in children with CF [1,2]. 13 
VO2peak represents the maximal amount of oxygen that can be delivered by the 14 
cardiovascular system and used at the muscles and defines functional aerobic 15 
capacity of a person [9,10]. In view of the potential usefulness of VO2peak as a guide 16 
to understanding any exercise limitation and for guiding the prescription of exercise 17 
programmes [11], our centre replaced an annual 6MWT with an annual CPET for all 18 
children and young people aged >7 years from May 2013. Here, we review our 19 
experience of measuring VO2peak using CPET and assess correlations with other more 20 
commonly used outcome measures such as pulmonary function test results and 21 
body mass index (BMI). We also investigated whether there was a difference in 22 
mean VO2peak depending on sex, the presence of at least one DF508 mutation or a 23 
history of intravenous antibiotic treatment in the preceding year and whether there 24 
were changes in aerobic capacity over time.  1 
MATERIALS AND METHODS 2 
Study participants 3 
We retrospectively analysed data for children and young people regularly attending 4 
the CF clinic at the Royal Hospital for Sick Children, Glasgow, who were >7 years and 5 
who had completed at least one CPET between May 2013 and April 2016. Clinic 6 
treatment routines remained unchanged during the study period and the 7 
participants were clinically stable when tested.  8 
 9 
Anthropometry  10 
Height was recorded to the nearest 0.1 cm using a stadiometer (Holtan Limited, UK) 11 
[12]. Weight was measured with minimal clothing to the nearest 0.1 kg (Seca 704, 12 
Germany). 13 
 14 
Pulmonary function testing 15 
Before CPET, spirometry and lung volumes were measured using a Jaeger 16 
Masterscreen Body Plethysmograph (Jaeger V5.4, Germany). All pulmonary function 17 
measurements were carried out by an experienced paediatric physiologist according 18 
to American Thoracic Society/European Respiratory Society standards [13,14,15]. 19 
 20 
Cardiopulmonary Exercise Testing  21 
A symptom-limited CPET was performed using an electronically braked cycle 22 
ergometer (Ergoline, Netherlands) with an incremental ramp protocol. Before each 23 
test, the metabolic cart (Jaeger, CPX, Germany) was calibrated according to the 1 
instructions of the manufacturer. We used a Godfrey exercise protocol [16] modified 2 
to minimise large increments in power output. The cycle ergometer ramp ranged 3 
between 6.5 and 25 W/min. The ramp was increased every 10 s to minimise power 4 
output perception. To achieve an optimal test duration of 8-12 min, power output 5 
based on weight, predicted for each participant [17], was divided by 10 to give the 6 
rate of ramp increase. Participants received verbal encouragement to achieve as 7 
near to a maximal test as possible. The test was stopped when the participant could 8 
not maintain a cadence > 60 rpm even with verbal encouragement.  VO2peak, peak 9 
oxygen pulse (VO2/HRpeak) and peak minute ventilation (VEpeak) were averaged over 10 
the last 30 s of the test. The gas exchange threshold was non-invasively identified 11 
using a combination of the ‘V slope’ method and ventilatory equivalents [9]. 12 
 13 
We considered a CPET technically satisfactory if one of the following three criteria 14 
were achieved at the end of the test: (1) HRpeak within 15 bpm of predicted maximum 15 
based on age; (2) respiratory exchange ratio (RER) > 1.1; or (3) plateau in VO2. 16 
 17 
Consent 18 
This study was a retrospective review of results from our standard clinical practice. 19 
As such, we did not seek informed consent for review of the data. All data of the 20 
patients were anonymised. 21 
 22 
Statistical Analysis 23 
Demographic data (age, sex, genotype and intravenous antibiotic use) were 1 
expressed as means and SDs. Forced expiratory volume in 1 s (FEV1) was expressed in 2 
absolute terms and as z-scores using all age reference ranges [18]. Static lung 3 
volumes were expressed in absolute values and as z-scores using UK-derived 4 
paediatric reference ranges [19]. VO2peak was expressed in L/min, mL/kg/min and as 5 
% predicted using a published paediatric reference range [17]. 6 
 7 
The relation between disease severity and VO2peak was assessed in two ways: first, as 8 
the relation between VO2peak and BMI since it is well recognised that poor nutritional 9 
status negatively affects pulmonary disease [20,21] and then, as the correlation 10 
between VO2peak and intravenous antibiotic use in the preceding year. We included 11 
children and young people treated with intravenous antibiotics either for a CF 12 
exacerbation or routinely as part of their CF management.  13 
 14 
To investigate relationships between VO2peak % predicted and FEV1 z-score, BMI z-15 
score and age, we used Pearson’s correlation coefficient. For differences between 16 
mean VO2peak % predicted with sex and intravenous antibiotics, we used a two-17 
sample t-test. A one-way analysis of variance was conducted to compare the effect 18 
of genotype (DF508 homozygous, DF508 heterozygous and ‘other’ genotypes) on 19 
VO2peak % predicted.  20 
 21 
We used a paired t-test to check for statistically significant differences between 22 
initial and consecutive CPET parameters of aerobic fitness (absolute VO2peak (L/min); 23 
relative VO2peak (mL/kg/min); VO2peak % predicted; and finally, allometrically scaled 24 
VO2peak (ml/kg2/3/min)). Relationships between the change in VO2peak % predicted and 1 
FEV1 and BMI z-scores were studied using Pearson’s correlation coefficient.  2 
 3 
RESULTS 4 
Pulmonary function & anthropometry. 5 
Anthropometry and pulmonary function are summarised for the 38 participants 6 
studied (17 males, 21 females) in tables 1 and 2. Seven participants had an FEV1 7 
consistently below the lower limit of normal [19].  8 
 9 
Table 1  10 
 11 
Table 2  12 
 13 
We were able to perform technically satisfactory assessments on 36/38 (95 %) of 14 
children and adolescents (Table 3); in two of them (both aged 7 years), the CPET was 15 
technically unsatisfactory due to poor cooperation. Aerobic capacity in children with 16 
CF was within a range consistent with a normal, healthy population (VO2peak of ≥85 % 17 
predicted [22]). Only five participants (13 %) had VO2peak of <85 % predicted, none of 18 
whom had reduced FEV1. Two participants desaturated to SpO2  (oxygen saturation 19 
as measured by pulse oximetry) <95 % at peak exercise. No ECG arrhythmias were 20 
detected. 21 
 22 
Table 3 23 
 24 
We found no significant correlation between VO2peak % predicted and FEV1 z-score (r 1 
=0.25, p=0.13), VO2peak % predicted and age (r =-0.24, p=0.15) or between VO2peak % 2 
predicted and BMI z-score (r =-0.05, p=0.77).  Using a two-sample t-test, we found 3 
no significant differences in mean VO2peak between males (107.9±19.1% predicted) vs 4 
females (107.1±17.0% predicted), p=0.90. Fourteen children and young people had 5 
received intravenous antibiotics in the preceding year with no significant differences 6 
in mean VO2peak if they had intravenous antibiotics (103.0±18.5% predicted) vs did 7 
not have intravenous antibiotics (110.1±17.1% predicted), p=0.23. Nineteen children 8 
and young people were DF508 homozygous, 16 were DF508 heterozygous and 3 had 9 
‘other’ genotypes with no significant effect of genotype on VO2peak (p=0.567). 10 
 11 
Figure 1. Change in VO2peak % predicted in 28 children and adolescents with CF 12 
measured between 12-18 months apart 13 
 14 
Table 4 15 
 16 
Consecutive annual CPET data were available for 28/38 (74%) children and young 17 
people (Figure 1), up to 18 months after the initial CPET due to CF annual review 18 
timings. The results for those who completed a second CPET are shown in table 4. 19 
Ten did not perform a repeat CPET: three transitioned to adult services; four did not 20 
attend; one had an intercurrent CF exacerbation; one CPET was unsatisfactory  due 21 
to submaximal  effort and there was insufficient staffing for one patient. Mean 22 
increase in body mass from test 1 to test 2 was 4.9 kg and height was 6.5 cm. There 23 
was no significant difference in mean change of absolute VO2peak (p=0.74). However, 24 
there was a statistically significant decline in VO2peak when it was related to body 1 
weight (p=0.001), to % predicted VO2peak (p=0.003), which includes sex and body 2 
weight in the predicting equation, and when using allometric scaling (mL/kg2/3/min) 3 
(p=0.03). Seventy-one per cent of patients had a decline in VO2peak relative to body 4 
weight. The mean decline relative to body weight was 3.8 mL/kg/min equivalent to 5 
an 8% decrease from baseline value. We found no significant correlation between 6 
the change in VO2peak % predicted and the change in FEV1 z-score (r=-0.07, p=0.72) or 7 
between VO2peak % predicted and the change in BMI z-score (r= 0.10, p=0.61). 8 
 9 
DISCUSSION 10 
In this study, the majority of our children and young people with CF had BMI and 11 
pulmonary function within the normal range, in keeping with UK CF registry data 12 
[23]. The majority also had VO2peakmeasurements within the normal range suggesting 13 
that they are an aerobically fit group.  14 
 15 
We found no significant correlation between FEV1 and VO2peak, presumably explained 16 
by the majority having normal lung function and aerobic capacity. It is recognised 17 
that FEV1 has to be significantly reduced to affect exercise capacity [24]. For 18 
example, McBride et al investigated 64 children with CF aged 8-11 years and found a 19 
statistically significant but weak correlation between FEV1 % predicted and VO2peak % 20 
predicted with an R2 value of 0.14[25].The most likely explanation for the differences 21 
with our study is a combination of a larger sample and a wider range of lung function 22 
and fitness. As only seven of our participants had an FEV1 below the lower limit of 23 
normal, it is perhaps not surprising that we did not see a relationship in a relatively 24 
mildly affected population [26].However, taken together, the low R2 value in a study 1 
by McBride and the absence of any significant correlation in our data suggest no 2 
strong relationship between FEV1 and VO2peak. Additionally, we did not demonstrate 3 
a significant correlation between the change in VO2peak % predicted and change in 4 
FEV1 or BMI z-score in our CF group, highlighting that these measurements cannot be 5 
used as a surrogate marker for aerobic fitness. There is an ongoing debate about 6 
factors that limit aerobic function in CF with suggestions of both central (e.g. 7 
impaired stroke volume [27]) and/or peripheral mechanisms (e.g. impaired muscle 8 
metabolism) being involved, apart from changes in lung function [28]. 9 
 10 
There are varying reports in the literature on the aerobic fitness of CF children. Nixon 11 
et al investigated VO2peak and its prognostic value in a group of 40 adults and 68 12 
children and adolescents in whom 65 % had an FEV1 of <65 % predicted. They found 13 
low aerobic capacity with a mean VO2peak of 70% predicted (35 mL/kg/min) [1]. More 14 
recently, Hulzebos et al reported on 127 adolescents with CF who had a mean FEV1 15 
of 78 ±15.6 % predicted and a VO2peak/kg 93±17.9% predicted [3]. Pianosi et al 16 
exclusively investigated children with CF and reported an initial VO2peak of 41.2 17 
mL/kg/min [2]. This would be classed as ‘fair’ aerobic fitness according to published 18 
paediatric reference values [24].  19 
 20 
More recent studies have included control groups and showed that children and 21 
adolescents with CF had a significantly reduced VO2peak when compared to healthy 22 
children. For example, Bongers et al in a group of 22 children with CF, found 23 
VO2peakto be significantly lower than healthy controls [29] and Saynor et al found a 24 
reduced aerobic capacity (mean VO2peak 36.3 mL/kg/min) in those with CF compared 1 
with controls [30]. 2 
 3 
Other studies have reported that nutritional status affects exercise capacity [31,32] 4 
but since very few of the children in our study had either an abnormal BMI or an 5 
abnormal VO2peak(≤84 % predicted (range 64 – 84)) [22] we were unable to 6 
demonstrate a significant a correlation. On reviewing the 3 participants with an 7 
abnormal VO2peak, all had normal BMI z-scores (-0.57, 1.13, 1.83).  8 
 9 
While the majority of our patients had normal CPET results, 71% demonstrated a 10 
decline in VO2peak relative to body weight on repeat testing 12- 18 months later. We 11 
recognise that in the absence of a control group and more extensive longitudinal 12 
data, it is difficult to exclude normal variation and regression to the mean as a cause 13 
of this decline and indeed, we found some evidence of regression to the mean. 14 
(Supplementary Figure).  15 
 16 
There is little reported data about what constitutes a significant decline in VO2peak in 17 
patients with CF. It is also unclear how changes with growth in weight and height 18 
should be accounted for when reporting VO2peak data, both in healthy children and in 19 
those with CF, particularly around puberty. In a review by Krahenbhul et al of data 20 
from healthy children, mean values of VO2peak relative to body weight were plotted 21 
against age in males and females over the age range 6-16 years [33]. Males had an 22 
unchanged VO2peak corrected for body weight over time, whereas females showed a 23 
decline from 52.0 to 40.5 mL/kg/min.  24 
 1 
It is recognized that correcting VO2peak for body mass has limitations and does not 2 
normalise the data [34,35]. Ratio scaling of VO2peak by body mass (as opposed to fat-3 
free mass) penalises females and those that are heavier than their aged match peers. 4 
Allometric scaling of VO2peakmay be a more reliable method to interpret changes in 5 
VO2peak[36], particularly in the transition at puberty. In a cross-sectional study using 6 
allometric scaling, Armstrong and Welsman reviewed prepubertal, circumpubertal 7 
and adult males and females, and found significant increases in VO2peak when 8 
allometrically scaled relative to weight in males throughout the maturational range, 9 
whereas females increased till puberty then remained stable [37]. In contrast, the 10 
Amsterdam Growth and Health Longitudinal Study recently reported aerobic fitness 11 
for approximately 650 adolescents over a 25-year period. They found that from 12 to 12 
17 years in both males and females, there was a downward trend in VO2peak relative 13 
to body weight.  However, when allometrically scaled, VO2peak in males did not 14 
decrease while females declined [38]. We found a mean decline relative to body 15 
weight of 3.8 mL/kg/min equivalent to an 8% decrease from baseline value. This is 16 
greater than the normal coefficient of variation reported in the literature for VO2peak 17 
(4.8%) when looking at biological quality control subjects [39], although the 18 
variability for young patients with CF is likely to be greater [40]. In our data, aerobic 19 
fitness declined significantly, irrespective of whether VO2peak was related to body 20 
weight, % predicted values or using allometric scaling (table 4), although the decline 21 
was least using allometric scaling. 22 
 23 
Pianosi et al reviewed annual CPET over a 5 year period in children with CF and 1 
found that VO2peak decreased in 70% of children with a mean annual decline of 2.1 2 
mL/kg/min [2]. Although measured over a much shorter time period, our results are 3 
similar. We can only speculate on the reasons for the decline in some children. 4 
Although changes in lung function measured as FEV1 were not correlated with 5 
changes in aerobic fitness, acute exacerbations as well as disease progression may 6 
have resulted in these patients participating in less physical activity with a 7 
consequent reduction in fitness. In others, an increase in fitness may result from the 8 
effects of planned exercise interventions.  Pianosi also showed that initial VO2peak did 9 
not affect the rate of decline and that patients with VO2peak< 32mL/kg/min exhibited 10 
a dramatic increase in mortality [2]. Further work will be required to investigate the 11 
value of repeated CPET tests in assessing exercise capacity in CF patients over time.   12 
 13 
Whilst the capital initial cost of CPET equipment is significant, the cost of 14 
consumables is minimal. Performing an annual CPET added minimal time to the CF 15 
annual review visit with 95% of children and young people aged above 7 years 16 
achieving technically satisfactory assessments. Nevertheless,  CPET is a more 17 
technically demanding test and can only be performed in a centre with the necessary 18 
equipment and appropriately trained staff. The majority of our patients engaged well 19 
with the test and participants reported that they enjoyed the challenge. Importantly, 20 
our respiratory physiotherapists found the results helpful in identifying children 21 
needing more targeted exercise advice. This emphasizes the value of CPET as a 22 
clinical tool to guide the prescription and monitoring of exercise programmes [41].  23 
 24 
Study limitations 1 
This was a retrospective review and we had no control group. Instead, we relied on 2 
published normal data for VO2peak, data based on a limited number of North 3 
American children and published in 1984. Future research should focus on providing 4 
up-to-date reference data for UK children.  5 
 6 
Only 74% (n = 28) completed a second CPET during the study period and the follow-7 
up period was relatively short at 12-18 months.  We continue to collect data in the 8 
expectation that longer follow up will give a more informed assessment of extent 9 
and value of changes in aerobic capacity over time.  10 
 11 
In the context of a paediatric clinical population, it was not feasible to perform a 12 
supramaximal test on each patient to verify a ‘true’ VO2peak as demonstrated by a 13 
plateau in VO2. The use of secondary criteria of HRpeak and RER may, therefore, 14 
underestimate the ‘true’ VO2peak [42]. We also did not routinely take body fat 15 
measurements but recognise that this may affect the VO2peak % predicted which uses 16 
body weight in the predictive equation. Finally, we had no standardised recording of 17 
physical activity levels of the children and adolescents in the 12-18 month interval 18 
between the first and second tests, data that might have been informative in 19 
assessing the effect of regular activity and/or exercise on aerobic capacity.  20 
 21 
CONCLUSION 22 
CPET is a feasible test of aerobic function at CF annual review. In our population with 23 
relatively mild CF, most had normal VO2peak. While most children and young people 24 
showed a decline in VO2peakover time, it remains to be shown if these declines are 1 
clinically significant or are part of normal biological variation.  2 
 3 
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Table 1  
 
Variable  mean SD 
Min, max 
Range 
Age (years) 11.0 2.39 7.3, 15.7 
Height (cm) 142.9 16.82 115, 180.8 
Body mass (kg) 36.9 12.32 20.2, 69.5 
BMI z-score 0.09 1.05 -2.2, 2.5 
 
Table 2  
 
Variable  mean SD 
Min, max 
Range 
FEV1 (L) 2.1 0.75 0.98, 4.06 
FEV1 z-score -0.77 1.24 -4.42, 2.24 
FEV1/FVC (%) 81 8.5 57, 96 
FEV1/FVC (%) z-score -0.99 1.24 -3.64, 1.55 
TLC (L) 3.7 1.15 2.04, 7.01 
TLC z-score 0.70 1.04 -1.08, 3.17 
RV (L) 1.1 0.49 0.58, 2.58 
RV z-score 0.59 1.75 -1.48, 6.61 
 
Table 3 
 
Variable Mean SD 
Min, Max 
Range 
Maximal Exercise parameters       
Absolute VO2peak (L·min-1) 1.6 0.52 0.88, 3.01 
Relative VO2peak (ml·kg-1·min-1) 42.8 7.99 29.2, 62.3 
VO2peak (% predicted) 107 17.6 74, 150 
VE max (L·min-1) 64 23.5 28, 137 
Breathing reserve (%) 19 19.8 -36, 54 
Heart Rate max (Beats·min-1) 188 10.2 160, 208 
Oxygen Pulse max (ml·beat-1) 8.6 2.77 4.0, 16.0 
End test SpO2 (%) 97 2.0 89, 100 
Peak power Output (W) 97 41.9 41, 212 
Relative Peak power output W·kg-1) 2.5 0.56 1.6, 3.8 
    
Submaximal Exercise    
VO2 at GET (ml·min-1) 822 216.1 415, 1455 
GET (% of VO2peak) 53 7.3 38, 70 
VO2/Work Rate (ml·W-1·min-1) 10.6 0.88 9.1, 12.3 
VE/VCO2 Slope 30.9 3.87 22.4, 44.0 
  GET - Gas exchange Threshold 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                            
 
 
 
Table 4 
 
Variable Mean1st CPET Mean2nd CPET Absolute 
Difference 
% Difference 
VO2peak (L·min-1) 1525 ± 479.7 1539 ± 420.4 14 1 
VO2peak Relative to bodyweight  
(ml·kg-1·min-1) 
42.7 ± 6.95 38.9 ± 8.19 -3.8 -9 
VO2peak % Predicted  
(includes sex and body weight) 
107 ± 16.6 99 ± 16.8 -8 -8 
VO2peak Allometrically scaled  
(ml·kg-2/3·min-1) 
137 ± 21.7 130 ± 21.9 -7 -6 
Body mass (kg) 36.2 ± 12.28 41.2 ± 13.51 4.9 13.6 
Body mass z-score 0.04 ± 0.97 0.06 ± 0.93   
Height (cm) 141.8 ± 15.11 148.3 ± 15.14 6.5 4.6 
Height z-score 0.03 ± 1.21 0.02 ± 1.13   
 
